HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target.

Souri, Zahra; Wierenga, Annemijn P A; Mulder, Arend; Jochemsen, Aart G; Jager, Martine J

Souri, Zahra; Wierenga, Annemijn P A; Mulder, Arend; Jochemsen, Aart G; Jager, Martine J.

Afiliação

Souri Z; Department of Ophthalmology, Leiden University Medical Center (LUMC), Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
Wierenga APA; Department of Ophthalmology, Leiden University Medical Center (LUMC), Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
Mulder A; Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center (LUMC), 2333 ZA Leiden, The Netherlands.
Jochemsen AG; Department of Cell and Chemical Biology, Leiden University Medical Center (LUMC), 2333 ZA Leiden, The Netherlands.
Jager MJ; Department of Ophthalmology, Leiden University Medical Center (LUMC), Albinusdreef 2, 2333 ZA Leiden, The Netherlands. m.j.jager@lumc.nl.

Cancers (Basel) ; 11(8)2019 Aug 07.

Article em En | MEDLINE | ID: mdl-31394860

Palavras-chave

BAP1; HLA Class I; HLA Class II; chromosome 3; inflammation; uveal melanoma

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google